For the first time, the H1N1 virus is resistant to human-to-human transmission

Five patients were located in a British hospital with a drug-resistant H1N1 flu virus. This is the first case of the spread of human-to-human transmission of influenza virus in the world.

First, two patients at Wales University Hospital showed flu symptoms, treated with Tamiflu but resistant to this drug. And then, this drug-resistant H1N1 flu virus spread to three other patients in the area.

Dailymail reports that of these 5 people, 2 people have recovered and been discharged, a person in special care, 2 others are still being treated with other antiviral drugs.

Picture 1 of For the first time, the H1N1 virus is resistant to human-to-human transmission

Tamiflu still works for the majority of H1N1 flu patients.(Photo: Dailymail)

There are many other patients in the same department who have H1N1 flu but do not know if they are infected with this resistant virus.

According to experts, the resistant virus is not more serious than the current H1N1 flu virus. Worldwide, 57 cases of Tamiflu resistance have been recorded.

In addition to drug resistance, the World Health Organization (WHO) also expressed concern about the transformation of the H1N1 flu virus in Norway and some other countries.

According to Xinhua, the Norwegian health sector has reported the discovery of this influenza virus mutation in two fatal patients and one in severe disease.

In addition, a number of other countries, such as Brazil, China, Japan, Mexico, Ukraine and the United States, have also discovered changes in the H1N1 flu virus. WHO scientists continue to study these cases.

However, the WHO claims that there is no evidence that these changes of the virus have caused an unusually high number of cases or more severe cases.

According to experts, the H1N1 flu virus changes but remains sensitive to antiviral drugs such as Tamiflu and Zanamivir. And that the current pandemic flu vaccine still works.

Pandemic H1N1 flu has killed more than 6,700 people worldwide.